{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:31:06Z","timestamp":1773477066660,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Besides clinical characteristics, easy-accessible laboratory markers could be of value to refine risk stratification in peripheral artery disease. In the current study, we investigated whether \u03b1-hydroxybutyrate dehydrogenase (HBDH) is associated with atherothrombotic events in 83 stable patients undergoing infrainguinal angioplasty and stenting. The primary endpoint was defined as the composite of the first occurrence of nonfatal myocardial infarction, nonfatal stroke or transient ischemic attack and cardiovascular death within 2 years after angioplasty and stenting, and occurred in 6 patients (7.2%). HBDH levels at baseline were significantly higher in patients who subsequently developed the primary endpoint (126\u2009U\/L [116\u2013137\u2009U\/L] vs. 105\u2009U\/L [95\u2013120\u2009U\/L]; p\u2009=\u20090.04). ROC curve analysis revealed that HBDH could distinguish between patients without and with future atherothrombotic events. A HBDH concentration\u2009\u2265\u2009115\u2009U\/L was identified as the best threshold to predict the composite endpoint, providing a sensitivity of 83.3% and a specificity of 71.4%, and was therefore defined as high HBDH. High HBDH was seen in 28 patients (33.7%). Ischemic events occurred significantly more often in patients with high HBDH than in patients with lower HBDH levels (5 vs. 1 patients, p\u2009=\u20090.007). In conclusion, HBDH is associated with the occurrence of atherothrombotic events after infrainguinal angioplasty with stent implantation. Future trials are warranted to study the predictive role of HBDH for ischemic outcomes and to investigate underlying mechanisms.<\/jats:p>","DOI":"10.1038\/s41598-019-54899-0","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T11:04:18Z","timestamp":1575371058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["\u03b1-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting"],"prefix":"10.1038","volume":"9","author":[{"given":"Silvia","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Koppensteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph W.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-7292","authenticated-orcid":false,"given":"Thomas","family":"Gremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"54899_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","volume":"51","author":"GM Welten","year":"2008","unstructured":"Welten, G. M. et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 51, 1588\u20131596, https:\/\/doi.org\/10.1016\/j.jacc.2007.11.077 (2008).","journal-title":"J Am Coll Cardiol"},{"key":"54899_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans, V. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39, 763\u2013816, https:\/\/doi.org\/10.1093\/eurheartj\/ehx095 (2018).","journal-title":"Eur Heart J"},{"issue":"Suppl S","key":"54899_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren, L. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45(Suppl S), S5\u201367, https:\/\/doi.org\/10.1016\/j.jvs.2006.12.037 (2007).","journal-title":"J Vasc Surg"},{"key":"54899_CR4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa051303","volume":"354","author":"M Schillinger","year":"2006","unstructured":"Schillinger, M. et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354, 1879\u20131888, https:\/\/doi.org\/10.1056\/NEJMoa051303 (2006).","journal-title":"N Engl J Med"},{"issue":"discussion 667","key":"54899_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jvs.2010.09.069","volume":"53","author":"I Gur","year":"2011","unstructured":"Gur, I. et al. Clinical outcomes and implications of failed infrainguinal endovascular stents. J Vasc Surg 53(discussion 667), 658\u2013666, https:\/\/doi.org\/10.1016\/j.jvs.2010.09.069 (2011).","journal-title":"J Vasc Surg"},{"key":"54899_CR6","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Davi","year":"2007","unstructured":"Davi, G. & Patrono, C. Platelet activation and atherothrombosis. N Engl J Med 357, 2482\u20132494, https:\/\/doi.org\/10.1056\/NEJMra071014 (2007).","journal-title":"N Engl J Med"},{"issue":"4","key":"54899_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1024\/0301-1526\/a000753","volume":"48","author":"Joseph Pultar","year":"2019","unstructured":"Pultar, J., Wadowski, P. P., Panzer, S. & Gremmel, T. Oral antiplatelet agents in cardiovascular disease. Vasa, 1\u201312, https:\/\/doi.org\/10.1024\/0301-1526\/a000753 (2018).","journal-title":"Vasa"},{"key":"54899_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/rth2.12115","volume":"2","author":"T Gremmel","year":"2018","unstructured":"Gremmel, T., Michelson, A. D., Frelinger, A. L. III & Bhatt, D. L. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2, 439\u2013449, https:\/\/doi.org\/10.1002\/rth2.12115 (2018).","journal-title":"Res Pract Thromb Haemost"},{"issue":"10117","key":"54899_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"Sonia S Anand","year":"2018","unstructured":"Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, https:\/\/doi.org\/10.1016\/S0140-6736(17)32409-1 (2017).","journal-title":"The Lancet"},{"key":"54899_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ahj.2006.07.016","volume":"152","author":"P Ohlmann","year":"2006","unstructured":"Ohlmann, P. et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J 152, 1161\u20131167, https:\/\/doi.org\/10.1016\/j.ahj.2006.07.016 (2006).","journal-title":"Am Heart J"},{"key":"54899_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0002-8703(98)70335-7","volume":"135","author":"R Dissmann","year":"1998","unstructured":"Dissmann, R., Linderer, T. & Schroder, R. Estimation of enzymatic infarct size: direct comparison of the marker enzymes creatine kinase and alpha-hydroxybutyrate dehydrogenase. Am Heart J 135, 1\u20139 (1998).","journal-title":"Am Heart J"},{"key":"54899_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/bja\/aeh148","volume":"93","author":"M Kemp","year":"2004","unstructured":"Kemp, M., Donovan, J., Higham, H. & Hooper, J. Biochemical markers of myocardial injury. Br J Anaesth 93, 63\u201373, https:\/\/doi.org\/10.1093\/bja\/aeh148 (2004).","journal-title":"Br J Anaesth"},{"key":"54899_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00043426-198100320-00010","volume":"3","author":"G Karayalcin","year":"1981","unstructured":"Karayalcin, G., Lanzkowsky, P. & Kari, A. B. Serum alpha-hydroxybutyrate dehydrogenase levels in children with sickle cell disease. Am J Pediatr Hematol Oncol 3, 169\u2013171 (1981).","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"54899_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF02550414","volume":"23","author":"I Apostolov","year":"1991","unstructured":"Apostolov, I. et al. Acute changes of serum markers for tissue damage after ESWL of kidney stones. Int Urol Nephrol 23, 215\u2013220 (1991).","journal-title":"Int Urol Nephrol"},{"key":"54899_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"CS Fox","year":"2010","unstructured":"Fox, C. S. et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121, 357\u2013365, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.865352 (2010).","journal-title":"Circulation"},{"key":"54899_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/ki.2008.233","volume":"75","author":"SP Surana","year":"2009","unstructured":"Surana, S. P., Riella, L. V., Keithi-Reddy, S. R., Charytan, D. M. & Singh, A. K. Acute coronary syndrome in ESRD patients. Kidney Int 75, 558\u2013562, https:\/\/doi.org\/10.1038\/ki.2008.233 (2009).","journal-title":"Kidney Int"},{"key":"54899_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1053\/j.ajkd.2005.02.018","volume":"45","author":"C Stigant","year":"2005","unstructured":"Stigant, C., Izadnegahdar, M., Levin, A., Buller, C. E. & Humphries, K. H. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis 45, 1002\u20131009 (2005).","journal-title":"Am J Kidney Dis"},{"key":"54899_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.amjcard.2016.03.034","volume":"117","author":"G Giustino","year":"2016","unstructured":"Giustino, G. et al. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol 117, 1877\u20131883, https:\/\/doi.org\/10.1016\/j.amjcard.2016.03.034 (2016).","journal-title":"Am J Cardiol"},{"key":"54899_CR19","doi-asserted-by":"publisher","first-page":"e114846","DOI":"10.1371\/journal.pone.0114846","volume":"9","author":"T Pilgrim","year":"2014","unstructured":"Pilgrim, T. et al. Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention. PLoS One 9, e114846, https:\/\/doi.org\/10.1371\/journal.pone.0114846 (2014).","journal-title":"PLoS One"},{"key":"54899_CR20","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3978\/j.issn.2072-1439.2015.11.56","volume":"7","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis. J Thorac Dis 7, 2041\u20132052, https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.11.56 (2015).","journal-title":"J Thorac Dis"},{"issue":"3","key":"54899_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/eci.12236","volume":"44","author":"Thomas Gremmel","year":"2014","unstructured":"Gremmel, T., Koppensteiner, R., Ay, C. & Panzer, S. Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. Eur J Clin Invest, https:\/\/doi.org\/10.1111\/eci.12236 (2014).","journal-title":"European Journal of Clinical Investigation"},{"key":"54899_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12933-018-0774-0","volume":"17","author":"S Lee","year":"2018","unstructured":"Lee, S., Ay, C., Kopp, C. W., Panzer, S. & Gremmel, T. Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. Cardiovasc Diabetol 17, 131, https:\/\/doi.org\/10.1186\/s12933-018-0774-0 (2018).","journal-title":"Cardiovasc Diabetol"},{"key":"54899_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2013.10.027","volume":"232","author":"T Gremmel","year":"2014","unstructured":"Gremmel, T. et al. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. Atherosclerosis 232, 119\u2013124, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.027 (2014).","journal-title":"Atherosclerosis"},{"key":"54899_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1160\/TH13-07-0558","volume":"111","author":"T Gremmel","year":"2014","unstructured":"Gremmel, T. et al. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 111, 474\u2013482, https:\/\/doi.org\/10.1160\/TH13-07-0558 (2014).","journal-title":"Thromb Haemost"},{"key":"54899_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1177\/1526602816655521","volume":"23","author":"T Gremmel","year":"2016","unstructured":"Gremmel, T. et al. Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease. J Endovasc Ther 23, 738\u2013743, https:\/\/doi.org\/10.1177\/1526602816655521 (2016).","journal-title":"J Endovasc Ther"},{"key":"54899_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross, R. Atherosclerosis\u2013an inflammatory disease. N Engl J Med 340, 115\u2013126 (1999).","journal-title":"N Engl J Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54899-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:47:59Z","timestamp":1671295679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54899-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54899"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54899-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18200"}}